Susan Dexter, Chief Technical Officer at Sonnet BioTherapeutics Holdings, Inc. (SONN), bought 10,000 shares at $0.70 ($7K) on 2023-06-14, disclosed to the SEC on 2023-06-15.
Open-market purchase of $7k SONN by Chief Technical Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.